Unique ID issued by UMIN | UMIN000053657 |
---|---|
Receipt number | R000061229 |
Scientific Title | A phase II study of cisplatin short hydration without diuretics. |
Date of disclosure of the study information | 2024/02/26 |
Last modified on | 2024/02/20 11:07:54 |
A phase II study of cisplatin short hydration without diuretics.
A phase II study of cisplatin short hydration without diuretics.
A phase II study of cisplatin short hydration without diuretics.
A phase II study of cisplatin short hydration without diuretics.
Japan |
Chemotherapy naive thoracic malignancy
Pneumology |
Malignancy
NO
To examine the efficacy and safety of cisplatin short hydration without diuretics.
Safety,Efficacy
Phase II
The proportion of patients who did not observe a Grade 2 or higher creatinine increase after the first cycle(defined as elevation in creatinine, CTCAE Ver. 5.0, based on the upper limit of the normal range (ULN) for serum creatinine at each institute)
1)The proportion of patients without grade 2 or higher creatinine increase at end of cycle
2)The number of chemotherapy cycles
3)Response rate
4)The proportion of adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Without diuretics administration
20 | years-old | <= |
74 | years-old | >= |
Male and Female
1)Thoracic malignancy
2)Patients who are eligible for combination chemotherapy with cisplatin (60 mg/m2 or more) (including combination therapy with immune checkpoint inhibitors and molecular target therapy drugs, and chemoradiotherapy)
3)Previously untreated with cisplatin-based chemotherapy
4)Patients aged 20 to 74 years
5)ECOG PS 0-1
6)WBC > 3000, Neu > 1500, Hb > 9g/dL, PLT > 100000, AST < 100IU/L, ALT < 100IU/L, T-Bil < 1.5mg/dL, SpO2 > 95% (room air)
7)Creatinine is below the upper limit normal range and creatinine clearance is 60mL/min or more
8)Patients with sufficient oral intake
9)Patients who have given written informed consent
1)Severe recurrent laryngeal nerve palsy or mediastinal mass
2)Pericardial effusion, pleural effusion, or ascites, with accumulation of fluid to a degree that requires drainage
3)Symptomatic brain metastases
4)Spinal metastases requiring urgent radiation or surgical treatment
5)Heart failure, unstable angina, myocardial infarction, acute kidney disease(within the past 6 months)
6)Complicated by poorly controlled diabetes even with continuous insulin use
7)Active infection(excluding viral hepatitis)
8)Receiving continuous systemic steroid therapy
9)Psychosis or comorbid psychiatric symptoms
10)Deemed inappropriate by attending physician
44
1st name | Kaoru |
Middle name | |
Last name | Kubota |
Nippon Medical School Hospital
Department of Pulmonary Medicine and Oncology
113-8603
1-1-5 Sendagi, Bunkyo-ku, Tokyo
0338222131
kkubota@nms.ac.jp
1st name | Tetsuya |
Middle name | |
Last name | Wako |
Nippon Medical School Hospital
Department of Pharmacy Services
1138603
1-1-5 Sendagi, Bunkyo-ku, Tokyo
0338222131
t-wako@nms.ac.jp
Nippon Medical School Hospital
None
Self funding
Nippon Medical School Hospital Drug Institutional Review Board
1-1-5 Sendagi, Bunkyo-ku, Tokyo
0338222131
inq-ccr@nms.ac.jp
NO
日本医科大学付属病院(東京都)
2024 | Year | 02 | Month | 26 | Day |
Unpublished
46
Completed
2019 | Year | 03 | Month | 04 | Day |
2020 | Year | 08 | Month | 20 | Day |
2019 | Year | 06 | Month | 01 | Day |
2023 | Year | 09 | Month | 01 | Day |
2024 | Year | 02 | Month | 20 | Day |
2024 | Year | 02 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061229
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |